These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 29755464)

  • 41. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.
    Guo ZS; Thorne SH; Bartlett DL
    Biochim Biophys Acta; 2008 Apr; 1785(2):217-31. PubMed ID: 18328829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
    van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
    J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
    Feola S; Russo S; Martins B; Lopes A; Vandermeulen G; Fluhler V; De Giorgi C; Fusciello M; Pesonen S; Ylösmäki E; Antignani G; Chiaro J; Hamdan F; Feodoroff M; Grönholm M; Cerullo V
    Front Immunol; 2022; 13():826164. PubMed ID: 35493448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer.
    Paiva LR; Silva HS; Ferreira SC; Martins ML
    Phys Biol; 2013 Apr; 10(2):025005. PubMed ID: 23492870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular insights and promise of oncolytic virus based immunotherapy.
    Iyer M; Ravichandran N; Karuppusamy PA; Gnanarajan R; Yadav MK; Narayanasamy A; Vellingiri B
    Adv Protein Chem Struct Biol; 2024; 140():419-492. PubMed ID: 38762277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
    Groeneveldt C; van den Ende J; van Montfoort N
    Cytokine Growth Factor Rev; 2023 Apr; 70():1-12. PubMed ID: 36732155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
    Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
    PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
    Kim Y; Clements DR; Sterea AM; Jang HW; Gujar SA; Lee PW
    Viruses; 2015 Dec; 7(12):6506-25. PubMed ID: 26690204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrating innate and adaptive immunity in oncolytic virus therapy.
    DePeaux K; Delgoffe GM
    Trends Cancer; 2024 Feb; 10(2):135-146. PubMed ID: 37880008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of oncolytic virus in tumor therapy.
    Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
    J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses.
    Bifulco M; Di Zazzo E; Napolitano F; Malfitano AM; Portella G
    Biochimie; 2023 Mar; 206():89-92. PubMed ID: 36273765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.